Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | NTRK2 |
Variant | A203T |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | NTRK2 A203T lies within Ig-like C2-type domain 1 of the Ntrk2 protein (UniProt.org). A203T results in increased cell surface expression and receptor dimerization of Ntrk2, and leads to increased phosphorylation of Ntrk2, Akt, and Erk, and IL3-independent growth in culture (PMID: 32315394). |
Associated Drug Resistance | |
Category Variants Paths |
NTRK2 mutant NTRK2 act mut NTRK2 A203T |
Transcript | NM_001018064.3 |
gDNA | chr9:g.84723596G>A |
cDNA | c.607G>A |
Protein | p.A203T |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001369537.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014760.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014752.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001018066.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252001.4 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252004.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252006.4 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014751.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_011518718.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001007097.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252003.4 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369546.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_011518720.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001018066.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001018065.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369542.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_011518718.4 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014755.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369540.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014751.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014755.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014758.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369548.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014753.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_006180.4 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001018064.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252001.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014759.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369544.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252007.4 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252003.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014754.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369539.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369549.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369534.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001291937.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014756.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014761.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_047423432.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369532.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369538.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001018064.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001291937.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014752.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_047423433.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369541.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014760.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_005252004.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_006180.6 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014753.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369545.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369547.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369533.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001018065.2 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001007097.3 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
XM_017014757.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
NM_001369543.1 | chr9:g.84723596G>A | c.607G>A | p.A203T | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NTRK2 A203T | hematologic cancer | sensitive | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Rozlytrek (entrectinib) decreased Ntrk2 phosphorylation and viability and increased apoptosis in a transformed cell line expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
NTRK2 A203T | hematologic cancer | sensitive | Foretinib | Preclinical - Cell culture | Actionable | In a preclinical study, Foretinib (GSK1363089) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
NTRK2 A203T | hematologic cancer | sensitive | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
NTRK2 A203T | hematologic cancer | sensitive | Crizotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xalkori (crizotinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
NTRK2 A203T | hematologic cancer | sensitive | Crenolanib | Preclinical - Cell culture | Actionable | In a preclinical study, Crenolanib (CP-868596) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
NTRK2 A203T | hematologic cancer | sensitive | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |
NTRK2 A203T | hematologic cancer | sensitive | Larotrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vitrakvi (larotrectinib) inhibited viability of transformed cells expressing NTRK2 A203T in culture (PMID: 32315394). | 32315394 |